Stock Chart

KROS

$11.36 +0.89%
Score: 53.9 HOLD
LEAPs: SELL $25
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $25
Premium: $0.80
Expiry: Jun 18, 2026
Target: $23
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 1.25x (vs SPY: 1.2x | vs QQQ: 1.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Rising Channel weak / forming — below our quality gate quality 52/100
A Rising Channel is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Lower rail breaks first 80% of the time (n=1,744) — a trend-exit tell, not a crash call
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About KROS - Keros Therapeutics, Inc. Common Stock

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Key Statistics

Market Cap $223M

This KROS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track KROS's price movements with trendlines, gamma walls, and key support/resistance levels.